Groer C E, Tidgewell K, Moyer R A, Harding W W, Rothman R B, Prisinzano T E, Bohn L M
Department of Pharmacology, the Ohio State University College of Medicine, 333 W 10th Avenue, 5184A Graves Hall, Columbus, OH 43210, USA.
Mol Pharmacol. 2007 Feb;71(2):549-57. doi: 10.1124/mol.106.028258. Epub 2006 Nov 7.
G protein-coupled receptor desensitization and trafficking are important regulators of opioid receptor signaling that can dictate overall drug responsiveness in vivo. Furthermore, different mu-opioid receptor (muOR) ligands can lead to varying degrees of receptor regulation, presumably because of distinct structural conformations conferred by agonist binding. For example, morphine binding produces a muOR with low affinity for beta-arrestin proteins and limited receptor internalization, whereas enkephalin analogs promote robust trafficking of both beta-arrestins and the receptors. Here, we evaluate muOR trafficking in response to activation by a novel mu-selective agonist derived from the naturally occurring plant product, salvinorin A. It is interesting that this compound, termed herkinorin, does not promote the recruitment of beta-arrestin-2 to the muOR and does not lead to receptor internalization. Moreover, whereas G protein-coupled receptor kinase overexpression can promote morphine-induced beta-arrestin interactions and muOR internalization, such manipulations do not promote herkinorin-induced trafficking. Studies in mice have shown that beta-arrestin-2 plays an important role in the development of morphine-induced tolerance, constipation, and respiratory depression. Therefore, drugs that can activate the receptor without recruiting the arrestins may be a promising step in the development of opiate analgesics that distinguish between agonist activity and receptor regulation and may ultimately lead to therapeutics designed to provide pain relief without the adverse side effects normally associated with the opiate narcotics.
G蛋白偶联受体脱敏和转运是阿片受体信号传导的重要调节因子,可决定体内整体药物反应性。此外,不同的μ-阿片受体(μOR)配体可导致不同程度的受体调节,这可能是由于激动剂结合赋予的不同结构构象所致。例如,吗啡结合产生的μOR对β-抑制蛋白的亲和力较低,且受体内化有限,而脑啡肽类似物则促进β-抑制蛋白和受体的大量转运。在此,我们评估了源自天然植物产物萨尔维诺林A的新型μ-选择性激动剂激活后μOR的转运情况。有趣的是,这种名为赫基诺林的化合物不会促进β-抑制蛋白-2募集到μOR,也不会导致受体内化。此外,虽然G蛋白偶联受体激酶过表达可促进吗啡诱导的β-抑制蛋白相互作用和μOR内化,但此类操作不会促进赫基诺林诱导的转运。对小鼠的研究表明,β-抑制蛋白-2在吗啡诱导的耐受性、便秘和呼吸抑制的发展中起重要作用。因此,能够在不募集抑制蛋白的情况下激活受体的药物,可能是开发区分激动剂活性和受体调节的阿片类镇痛药的一个有前景的步骤,并最终可能导致旨在提供疼痛缓解而无通常与阿片类麻醉剂相关的不良副作用的治疗方法。